- Home
- CHI vs OLMA Comparison
CHI vs OLMA Comparison
Compare CHI & OLMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CHI | OLMA |
|---|---|---|
| Founded | 2002 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 994.9M |
| IPO Year | 2002 | 2020 |
Fundamental Metrics
Financial Performance| Metric | CHI | OLMA |
|---|---|---|
| Price | $13.47 | $11.81 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 10 |
| Target Price | N/A | ★ $44.89 |
| AVG Volume (30 Days) | 191.8K | ★ 2.0M |
| Earning Date | 01-01-0001 | 05-08-2026 |
| Dividend Yield | ★ 9.90% | N/A |
| EPS Growth | N/A | ★ 15.00 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $10.10 | $4.37 |
| 52 Week High | $13.50 | $36.26 |
Technical Indicators
Market Signals| Indicator | CHI | OLMA |
|---|---|---|
| Relative Strength Index (RSI) | 63.91 | 50.35 |
| Support Level | $12.48 | $7.79 |
| Resistance Level | $13.48 | $14.29 |
| Average True Range (ATR) | 0.27 | 0.80 |
| MACD | 0.00 | 0.22 |
| Stochastic Oscillator | 96.66 | 65.84 |
Price Performance
Historical ComparisonAbout CHI Calamos Convertible Opportunities and Income Fund
CALAMOS CONVERTIBLE OPPORTUNITIES & INCOME FUND operates as a closed-end management investment company. Its investment objective is to provide total return through a combination of capital appreciation and current income. The Fund invests in convertible securities and high-yield securities.
About OLMA Olema Pharmaceuticals Inc.
Olema Pharmaceuticals inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of next generation targeted therapies for women's cancers. Its therapies offer the potential to improve outcomes for women living with cancer. The company has completed discovery and preclinical studies of OP-1250. OP-3136 is another drug candidate in the company's product pipeline.